| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,250 shares of the Company's common stock at an exercise price per share of $8.53, which was the closing price on May 8, 2025, and re. |
businesswire.com |
2025-05-09 20:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript |
Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob Goeltz - CFO Juan Jaen - President Conference Call Participants Peter Lawson - Barclays Daina Graybosch - Leerink Partners Yigal Nochomovitz - Citigroup Umer Raffat - Evercore Eva Fortea - Wells Fargo Emily Bodnar - HC Wainwright Operator Hello, everyone. And welcome to Arcus Biosciences First Quarter 2025 Earnings and Financial Results Call. |
seekingalpha.com |
2025-05-07 00:17:10 |
Czytaj oryginał (ang.) |
| Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates |
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.05 per share a year ago. |
zacks.com |
2025-05-06 23:10:44 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 39,750 shares of the Company's common stock at an exercise price per share of $8.11, which was the closing price on April 23, 2025 and re. |
businesswire.com |
2025-04-24 20:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the c. |
businesswire.com |
2025-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 16,960 shares of the Company's common stock at an exercise price per share of $7.04, which was the closing price on April 8, 2025, and re. |
businesswire.com |
2025-04-09 20:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts |
Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board presence indicate confidence in Arcus, despite the challenges faced with domvanalimab. Arcus has a diverse pipeline targeting pancreatic and renal cell carcinoma, with promising Phase 3 trials that could significantly boost the stock. |
seekingalpha.com |
2025-04-02 19:48:53 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted twelve new employees options to purchase a total of 42,920 shares of the Company's common stock at an exercise price per share of $9.12, which was the closing price on March 24, 2025, an. |
businesswire.com |
2025-03-25 18:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences to Participate in Two Upcoming Investor Conferences |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2025 Date: Wednesday, March 12th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Barclays 27th. |
businesswire.com |
2025-02-26 18:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates |
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.08 per share a year ago. |
zacks.com |
2025-02-25 21:01:24 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 5,550 shares of the Company's common stock at an exercise price per share of $11.07, which was the closing price on February 21, 2025, and. |
businesswire.com |
2025-02-24 18:35:00 |
Czytaj oryginał (ang.) |
| Biotechs Highlight 6 Stocks Insiders Are Buying Now |
Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings. |
247wallst.com |
2025-02-23 10:45:43 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that Gilead's time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has announced the pricing of a $150 million common stock offering, which is subject to customary closing conditions and includes participation from new and existing. |
businesswire.com |
2025-02-18 08:57:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the pricing of an underwritten offering of 13,636,364 shares of its common stock at an offering price of $11.00 per share, for total gross proceeds of approximately $150 million, before deducting underwriting discounts and commissions and offering expenses payable. |
businesswire.com |
2025-02-18 08:52:00 |
Czytaj oryginał (ang.) |
| New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. “The newest d. |
businesswire.com |
2025-02-15 17:45:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock. |
businesswire.com |
2025-02-11 18:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that data from the ARC-20 study will be presented in a rapid oral session at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium taking place February 13 – 15, 2025, in San Francisco, CA. The oral presentation will highligh. |
businesswire.com |
2025-02-10 19:00:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 31,800 shares of the Company's common stock at an exercise price per share of $13.33, which was the closing price on January 23, 2024, and. |
businesswire.com |
2025-01-24 18:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025 |
Arcus Biosciences has interesting combination therapies that target several diseases like NSCLC, RCC, GI, and pancreatic cancers. The company has a few ongoing Phase 3 trials, some of which will report important updates in 2025. One of Domvanalimab's combinations showed that it can help overall survival by a whopping 36% in NSCLC. It also had lower discontinuation rates than chemotherapy. |
seekingalpha.com |
2025-01-15 00:51:59 |
Czytaj oryginał (ang.) |
| Arcus: Excellent Pipeline And Collaborations, Cash Runway |
Arcus Biosciences presents a strong buying opportunity due to positive data, Gilead's increased stake, and a robust pipeline with significant market potential. Lead molecule domvanalimab shows promising phase 3 trial results in lung and gastrointestinal cancers, with substantial survival benefits and market potential of $10bn. Casdatifan, an HIF-2α inhibitor, has shown superior data in clear cell renal cell carcinoma, positioning it as a leading candidate in a $2bn market. |
seekingalpha.com |
2025-01-13 10:00:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 66,900 shares of the Company's common stock at an exercise price per share of $15.96, which was the closing price on December 23, 2024,. |
businesswire.com |
2024-12-24 18:05:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Tuesday, January 14th, 2025, at 3:45pm PT. A live webcast of the presentation will be avail. |
businesswire.com |
2024-12-19 18:05:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 7,400 shares of the Company's common stock at an exercise price per share of $17.47 which was the closing price on December 9, 2024, and. |
businesswire.com |
2024-12-10 18:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,000 shares of the Company's common stock at an exercise price per share of $14.56, which was the closing price on November 25, 2024,. |
businesswire.com |
2024-12-03 18:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences to Participate in Two Upcoming Investor Conferences |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7th Annual HealthCONx Conference Date: Tuesday, December 3rd, 2024 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 7:55 a.m. ET Citi 2024. |
businesswire.com |
2024-11-19 18:05:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company's common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and. |
businesswire.com |
2024-11-12 18:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates |
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.94 per share a year ago. |
zacks.com |
2024-11-06 20:41:20 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules — targeting TIGIT, HIF-2a, CD73, the A2a/A2b receptors, CD-39, AXL and PD-1 — across multiple common cancers. “Through. |
businesswire.com |
2024-11-06 18:22:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 28,600 shares of the Company's common stock at an exercise price per share of $17.33, which was the closing price on October 23, 2024, and. |
businesswire.com |
2024-10-24 20:35:00 |
Czytaj oryginał (ang.) |
| First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today presented the first clinical activity data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics i. |
businesswire.com |
2024-10-24 11:30:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended September 30th, 2024. Investors interested in listening to. |
businesswire.com |
2024-10-22 20:05:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 24,100 shares of the Company's common stock at an exercise price per share of $17.47, which was the closing price on October 8, 2024, and. |
businesswire.com |
2024-10-09 20:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients wi. |
businesswire.com |
2024-10-02 20:05:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted five new employees options to purchase a total of 38,600 shares of the Company's common stock at an exercise price per share of $15.71, which was the closing price on September 23, 2024, a. |
businesswire.com |
2024-09-24 20:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones |
Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdastifan leading the way in targeting large oncology markets. Domvanalimab, a Phase 3 anti-TIGIT antibody for NSCLC and GI cancers, could significantly impact treatment upon approval. Casdastifan is advancing to Phase 3 for renal cell carcinoma and may outperform Merck's Belzutifan. |
seekingalpha.com |
2024-09-23 05:53:07 |
Czytaj oryginał (ang.) |
| Arcus Biosciences Announces New Employment Inducement Grants |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,100 shares of the Company's common stock at an exercise price per share of $18.01, which was the closing price on August 23, 2024, and. |
businesswire.com |
2024-08-26 20:35:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences to Participate in Two Upcoming Investor Conferences |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Wednesday, September 4th, 2024 at 4:55 p.m. ET Location: New York, NY Format: Fireside Chat Cantor Fitzgerald G. |
businesswire.com |
2024-08-21 20:05:00 |
Czytaj oryginał (ang.) |
| Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy) |
Domvanalimab shows promising results in gastric cancer, with a 56% response rate and median progression-free survival of 12.9 months. Quemlicustat sees progress with Taiho exercising rights in Asia, while etrumadenant shows positive results in colorectal cancer trials. Arcus Biosciences pipeline continues to show potential, but TIGIT failures in the industry pose a significant risk to the company's outlook. |
seekingalpha.com |
2024-08-09 21:31:32 |
Czytaj oryginał (ang.) |
| Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript |
Arcus Biosciences, Inc. (NYSE:RCUS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Pia Eaves – Vice President-Investor Relations and Strategy Terry Rosen – Chief Executive Officer Jennifer Jarrett – Chief Operating Officer Bob Goeltz – Chief Financial Officer Dimitry Nuyten – Chief Medical Officer Conference Call Participants Yigal Nochomovitz – Citi Jonathan Miller – Evercore Daina Graybosch – Leerink Partners Asthika Goonewardene – Truist Securities Operator Good afternoon, thank you for attending today's Arcus Biosciences Second Quarter 2024 Earnings Call. My name is Tamiya and I will be your moderator for today's call. |
seekingalpha.com |
2024-08-09 21:21:08 |
Czytaj oryginał (ang.) |
| Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates |
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.04 per share a year ago. |
zacks.com |
2024-08-08 23:15:57 |
Czytaj oryginał (ang.) |